1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Melinta Therapeutics, Inc - Strategic SWOT Analysis Review

Melinta Therapeutics, Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.

Highlights

Melinta Therapeutics, Inc. (Melinta) is a biopharmaceutical company that focuses on the development of novel antibiotics. Its drugs are intended to treat the various bacterial infections. The company's lead product delafloxacin is an investigational antibiotic. The Phase III drug candidate is in development for acute bacterial skin and skin structure infections (ABSSSI) and uncomplicated gonorrhea. Other products in the pipeline include radezolid and next generation macrolides among others. The products are based on its ribosome crystallography platform, engineered to overcome the problem of drug resistance. Melinta is headquartered at New Haven, Connecticut, the US.

Melinta Therapeutics, Inc Key Recent Developments

May 19, 2015: Melinta Therapeutics Study Demonstrates Significant Burden of Obesity on Patients' Recovery from Acute Bacterial Skin Infections

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Table Of Contents

Melinta Therapeutics, Inc - Strategic SWOT Analysis Review
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 - About the Company 6
Melinta Therapeutics, Inc - Key Facts 6
Melinta Therapeutics, Inc - Key Employees 7
Melinta Therapeutics, Inc - Key Employee Biographies 8
Melinta Therapeutics, Inc - Major Products and Services 9
Melinta Therapeutics, Inc - Pharmaceutical Pipeline Products Data 10
Melinta Therapeutics, Inc, Pipeline Products by Therapy Area 10
Melinta Therapeutics, Inc, Pipeline Products by Development Phase 11
Melinta Therapeutics, Inc - History 14
Melinta Therapeutics, Inc - Company Statement 16
Melinta Therapeutics, Inc - Locations And Subsidiaries 17
Head Office 17
Other Locations and Subsidiaries 17
Section 2 - Company Analysis 18
Melinta Therapeutics, Inc - Business Description 18
Melinta Therapeutics, Inc - Corporate Strategy 19
Melinta Therapeutics, Inc - SWOT Analysis 20
SWOT Analysis - Overview 20
Melinta Therapeutics, Inc - Strengths 20
Strength - Agreements and Collaborations 20
Strength - Expertise In-house Research Activities 20
Strength - Proprietary Technology 20
Melinta Therapeutics, Inc - Weaknesses 21
Weakness - Lack of Product Revenue 21
Weakness - Lack of Capital Resources 21
Melinta Therapeutics, Inc - Opportunities 22
Opportunity - Growing Incidence of Infectious Diseases 22
Opportunity - Market Potential: Antibiotics 22
Opportunity - Pipeline Portfolio 22
Melinta Therapeutics, Inc - Threats 23
Threat - Uncertain RandD Outcomes 23
Threat - Tough Credit Market Conditions 23
Threat - Stringent Government Regulations 23
Melinta Therapeutics, Inc - Key Competitors 24
Section 3 - Company's Lifesciences Financial Deals and Alliances 25
Melinta Therapeutics, Inc, Pharmaceuticals and Healthcare, Deals By Year, 2010 to YTD 2016 25
Melinta Therapeutics, Inc, Pharmaceuticals and Healthcare, Deals By Type, 2010 to YTD 2016 26
Melinta Therapeutics, Inc, Recent Deals Summary 27
Section 4 - Company's Recent Developments 28
May 19, 2015: Melinta Therapeutics Study Demonstrates Significant Burden of Obesity on Patients' Recovery from Acute Bacterial Skin Infections 28
Section 5 - Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Melinta Therapeutics, Inc, Key Facts 6
Melinta Therapeutics, Inc, Key Employees 7
Melinta Therapeutics, Inc, Key Employee Biographies 8
Melinta Therapeutics, Inc, Major Products and Services 9
Melinta Therapeutics, Inc, Number of Pipeline Products by Therapy Area 10
Melinta Therapeutics, Inc, Number of Pipeline Products by Development Stage 11
Melinta Therapeutics, Inc, Pipeline Products By Therapy Area and Development Phase 12
Melinta Therapeutics, Inc, History 14
Melinta Therapeutics, Inc, Other Locations 17
Melinta Therapeutics, Inc, Key Competitors 24
Melinta Therapeutics, Inc, Pharmaceuticals and Healthcare, Deals By Year, 2010 to YTD 2016 25
Melinta Therapeutics, Inc, Pharmaceuticals and Healthcare, Deals By Type, 2010 to YTD 2016 26
Melinta Therapeutics, Inc, Recent Deals Summary 27

List of Figures
Melinta Therapeutics, Inc, Pipeline Products by Therapy Area 10
Melinta Therapeutics, Inc, Pipeline Products by Development Phase 11
Melinta Therapeutics, Inc, Pharmaceuticals and Healthcare, Deals By Year, 2010 to YTD 2016 25
Melinta Therapeutics, Inc, Pharmaceuticals and Healthcare, Deals by Type, 2010 to YTD 2016 26

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2016

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2016’, provides in depth analysis ...

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016’, provides in depth analysis ...

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.